Analysis of Factors Influencing the Quality of Bowel Preparation Before Colonoscopy in IBD Patients

NCT07335705 | Recruiting

• 1 other identifier: CHEC2025-448
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objectives of this project are twofold. On the one hand, it aims to investigate the current status of bowel preparation protocols and their quality in IBD patients undergoing colonoscopy, particularly focusing on the implementation of these protocols across hospitals following the release of the 2023 bowel preparation guidelines. This will further standardize and optimize bowel preparation practices in China. On the other hand, the project seeks to identify and examine various risk factors contributing to poor bowel preparation quality in IBD patients, analyze their correlation with bowel preparation scores, and develop a risk prediction model for failed bowel preparation. This will provide a theoretical foundation for formulating personalized bowel preparation regimens tailored to individual patient conditions in the future.

Conditions

IBD (Inflammatory Bowel Disease); Colonoscopy; Colonoscopy: Bowel Preparation

Keywords

IBD; Colonoscopy; Bowel preparation

Outcome Measures

Primary Outcomes (1)

• adequate bowel preparation rate

  Proportion of subjects with Boston Bowel Preparation Scale (BBPS) scores ≥ 2 in all bowel segments.

  The adequate bowel preparation rate can be assessed immediately upon completion of colonoscopy

Secondary Outcomes (1)

• Patient Satisfaction

  immediately upon completion of colonoscopy

Study Arms (1)

Observational Cohort for Bowel Preparation in IBD Patients

Patients aged 18 years or older diagnosed with Inflammatory Bowel Disease (IBD) and scheduled for a colonoscopy, who undergo standard bowel preparation procedures followed by colonoscopy examination and questionnaire completion.

Other: Standard Pre-colonoscopy Bowel Preparation Protocol

Interventions

Standard Pre-colonoscopy Bowel Preparation Protocol OTHER

This involves standard clinical instructions including a low-residue diet prior to colonoscopy and the administration of bowel cleansing agents (e.g., Polyethylene Glycol) according to the split-dose regimen as per each participating center's routine practice. The timing, dosage, and specific agent used follow existing institutional guidelines.

Observational Cohort for Bowel Preparation in IBD Patients

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

adult patients (aged ≥18 years) diagnosed with Inflammatory Bowel Disease (IBD) according to the 2023 Chinese guidelines, who are scheduled to undergo a colonoscopy

You may qualify if:

• Patients aged 18 years or older, of any gender, scheduled for colonoscopy;
• Patients diagnosed with Inflammatory Bowel Disease (IBD) according to the 2023 edition of the Guidelines for the Diagnosis and Treatment of Inflammatory Bowel Disease;
• Voluntary participation in this study and provision of signed informed consent.

You may not qualify if:

• History of acute myocardial infarction (within the past 6 months), severe cardiac, hepatic, or renal insufficiency, or psychiatric disorders;
• Current use of anticoagulants (e.g., aspirin, warfarin) or presence of coagulation disorders;
• Pregnant or lactating women;
• Acute intestinal infection within the past 2 weeks;
• History of colorectal tumors, familial adenomatous polyposis, or Peutz-Jeghers syndrome;
• History of intestinal obstruction, perforation, stenosis, or any other condition preventing completion of the examination;
• Severe hearing impairment, cognitive dysfunction, or inability to cooperate with the survey;
• Individuals already enrolled in this study who schedule a repeat colonoscopy;
• Currently participating in another clinical observational trial or having participated in any other clinical trial within the past 60 days;
• Refusal to sign the written informed consent form.

Sponsors & Collaborators

• Changhai Hospital: lead
• The First Affiliated Hospital of Anhui Medical University: collaborator
• Ankang Central Hospital: collaborator
• First People's Hospital of Hangzhou: collaborator
• Jiangmen Central Hospital: collaborator
• Subei People's Hospital of Jiangsu Province: collaborator
• Xijing Hospital: collaborator
• The Affiliated Hospital of Qingdao University: collaborator
• RenJi Hospital: collaborator
• Ruijin Hospital: collaborator
• Shanghai 10th People's Hospital: collaborator
• ShuGuang Hospital: collaborator
• Shengli Oilfield Hospital: collaborator

Study Sites (1)

Changhai Hospital

Shanghai, Shanghai Municipality, 200433, China

RECRUITING

MeSH Terms

Conditions

Inflammatory Bowel Diseases

Condition Hierarchy (Ancestors)

Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Intestinal Diseases

Central Study Contacts

Zhao-shen Li, M.D.

CONTACT

13386273620; zhaoshenli@hotmail.com

Zi-xuan He, M.D.

CONTACT

zixuan931004@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: professor

Study Record Dates

• First Submitted: December 8, 2025
• First Posted: January 13, 2026
• Study Start: December 8, 2025
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): October 1, 2026
• Last Updated: April 22, 2026

Record last verified: 2026-04

Locations

CN (1)